Patents Represented by Attorney Maureen S. Gibbons
  • Patent number: 6620816
    Abstract: This invention provides a method of treating a tumor in a warm-blooded animal, including humans, by administering, in combination, an anti-tumor effective amount of tegafur, uracil, folinic acid or pharmaceutically acceptable salt thereof and cyclophosphamide.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: September 16, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Eric P. Winer, Craig A. Bunnell, Jody Ressler-Tatro, Terry S. Dugan
  • Patent number: 6602883
    Abstract: Disclosed are quinoline and benzazepine derivatives that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogenic protein Ras. Thus, the compounds are useful as anti-cancer agents. The compounds are also useful in the treatment of diseases other than cancer.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: August 5, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rajeev S. Bhide, Charles Z. Ding, John T. Hunt, Soong-Hoon Kim, Katerina Leftheris
  • Patent number: 6537988
    Abstract: The present invention provides a synergistic method for the treatment of cancer which comprises administering to a mammalian specie in need thereof a synergistically, therapeutically effective amount of: (1) at least agent selected from the group consisting of cytotoxic agents and cytostatic agents, and (2) a compound of formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the synergistic treatment of cancer which comprises at least one agent selected from the group consisting of antiproliferative cytotoxic agents and antiproliferative cytostatic agents, a compound of formula I, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: March 25, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francis Y. Lee
  • Patent number: 6458783
    Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: October 1, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Charles Z. Ding, John T. Hunt, Katerina Leftheris, Rajeev S. Bhide
  • Patent number: 6455523
    Abstract: Inhibition of farnesyl transferase, which is an enzyme involved in ras ocogene expression, is effected by compounds of the formulas their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs and solvates thereof inhibit farnesyl protein transferase which is an enzyme involved in ras oncogene expression.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: September 24, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Charles Z. Ding, Soong-Hoon Kim, John T. Hunt, Toomas Mitt, Rajeev Bhide, Katerina Leftheris